[Initial experiences with HCV detection and confirmation tests of the 3rd generation]

Area of Science:

• Hepatology
• Immunology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection is a significant global health concern.
• Accurate and sensitive diagnostic assays are crucial for HCV detection and management.
• Current second-generation anti-HCV enzyme immunoassays (EIAs) have limitations in sensitivity and specificity.

Purpose of the Study:

• To compare the reactivity of a novel 3rd-generation anti-HCV EIA with a 2nd-generation EIA.
• To evaluate the performance of the anti-HCV Recombinant immunoblot assay 2 (RP-2 RIBA) for indeterminate samples.
• To assess the diagnostic significance of isolated NS5 region antigen reactivity.

Main Methods:

• Comparative analysis of a 3rd-generation anti-HCV EIA and a 2nd-generation anti-HCV EIA.
• Testing of serum specimens from healthy blood donors and patients at risk for HCV infection.
• Validation of indeterminate results using Western blot and RP-2 RIBA.

Main Results:

• The 3rd-generation EIA detected isolated NS5 reactivity in 3 samples, later confirmed by Western blot and RP-2 RIBA.
• One patient showed reactivity with the 2nd-generation EIA only (anti-c33c antibodies).
• The RP-2 RIBA identified 9 of 15 indeterminate samples as reactive, showing higher sensitivity and specificity.

Conclusions:

• The anti-HCV RP-2 RIBA exhibits enhanced sensitivity and specificity compared to the 2nd-generation EIA.
• The clinical relevance of isolated NS5 EIA reactivity requires further investigation.
• The 3rd-generation EIA shows potential but needs validation for isolated NS5 reactivity.